Fidelis Capital Partners LLC Acquires 285 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Fidelis Capital Partners LLC lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,465 shares of the pharmaceutical company’s stock after purchasing an additional 285 shares during the period. Fidelis Capital Partners LLC’s holdings in Vertex Pharmaceuticals were worth $2,569,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Groesbeck Investment Management Corp NJ boosted its position in shares of Vertex Pharmaceuticals by 1.2% during the 2nd quarter. Groesbeck Investment Management Corp NJ now owns 1,794 shares of the pharmaceutical company’s stock valued at $841,000 after purchasing an additional 21 shares in the last quarter. Institute for Wealth Management LLC. boosted its holdings in Vertex Pharmaceuticals by 0.6% in the second quarter. Institute for Wealth Management LLC. now owns 3,586 shares of the pharmaceutical company’s stock worth $1,681,000 after acquiring an additional 22 shares in the last quarter. Drive Wealth Management LLC boosted its holdings in Vertex Pharmaceuticals by 2.0% in the second quarter. Drive Wealth Management LLC now owns 1,101 shares of the pharmaceutical company’s stock worth $516,000 after acquiring an additional 22 shares in the last quarter. Daymark Wealth Partners LLC boosted its holdings in Vertex Pharmaceuticals by 2.8% in the third quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company’s stock worth $374,000 after acquiring an additional 22 shares in the last quarter. Finally, Grove Bank & Trust boosted its holdings in Vertex Pharmaceuticals by 5.7% in the third quarter. Grove Bank & Trust now owns 410 shares of the pharmaceutical company’s stock worth $191,000 after acquiring an additional 22 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on VRTX. HC Wainwright reissued a “buy” rating and issued a $600.00 price objective on shares of Vertex Pharmaceuticals in a research note on Monday, October 21st. Truist Financial reissued a “buy” rating and issued a $550.00 price objective (up from $508.00) on shares of Vertex Pharmaceuticals in a research note on Monday, August 5th. Royal Bank of Canada lowered their price objective on Vertex Pharmaceuticals from $431.00 to $425.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. UBS Group increased their price objective on Vertex Pharmaceuticals from $477.00 to $562.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Finally, Morgan Stanley increased their price objective on Vertex Pharmaceuticals from $462.00 to $474.00 and gave the stock an “equal weight” rating in a research note on Tuesday, October 1st. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Hold” and an average target price of $492.92.

Insider Transactions at Vertex Pharmaceuticals

In other news, Chairman Jeffrey M. Leiden sold 3,784 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $499.00, for a total value of $1,888,216.00. Following the completion of the transaction, the chairman now directly owns 9,994 shares of the company’s stock, valued at $4,987,006. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Chairman Jeffrey M. Leiden sold 3,784 shares of Vertex Pharmaceuticals stock in a transaction on Friday, August 30th. The stock was sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the completion of the sale, the chairman now owns 9,994 shares of the company’s stock, valued at approximately $4,987,006. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sangeeta N. Bhatia sold 646 shares of Vertex Pharmaceuticals stock in a transaction on Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the sale, the director now directly owns 4,435 shares of the company’s stock, valued at $2,217,500. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,005 shares of company stock valued at $5,988,066 over the last three months. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $470.36 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26. The business has a fifty day simple moving average of $475.03 and a two-hundred day simple moving average of $463.79. Vertex Pharmaceuticals Incorporated has a 1 year low of $341.90 and a 1 year high of $510.64. The company has a market capitalization of $121.40 billion, a P/E ratio of -231.70 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The company had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.66 billion. During the same period in the previous year, the business earned $3.53 earnings per share. Vertex Pharmaceuticals’s revenue was up 6.1% on a year-over-year basis. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post -2.11 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.